Navigation Links
Jazz Pharmaceuticals, Inc. Announces LUVOX CR Launch Plans and Reports Development Pipeline Progress at Investor Day Presentation
Date:3/13/2008

"Obsessive compulsive disorder and social anxiety disorder are two very serious and debilitating anxiety disorders that affect millions of patients in the U.S. We are excited to be near the launch of a product that has been proven safe and effective for treating both of these conditions," said Robert M. Myers, Jazz Pharmaceuticals' President. "A comprehensive commercialization plan, including physician education, pricing and reimbursement and manufacturing and distribution, is in place. Jazz Pharmaceuticals' sales force of approximately 200 experienced professionals has been trained and is ready to promote LUVOX CR to psychiatrists for the treatment of OCD and SAD. We look forward to a successful launch."

Jazz Pharmaceuticals' sales representatives currently promote XYREM(R) (sodium oxybate) for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy to sleep specialists, neurologists and psychiatrists. XYREM net sales increased by 34 percent, from $29 million in 2006 to $39 million in 2007. XYREM net sales are expected to be in the range of $45 million to $55 million during 2008.

Jazz Pharmaceuticals projects sales of products in 2008 between $90 million and $120 million, with gross margin on net product sales of approximately 80 percent.

"2007 was a year of strong accomplishments, with increased sales and brand awareness for XYREM and the expansion of our commercial organization in preparation for the pending launch of LUVOX CR," added Mr. Myers.

Development-Stage Portfolio Updates

Jazz Pharmaceuticals announced that it has achieved more than 80 percent enrollment in the first of two ongoing Phase III clinical trials of JZP-6 (sodium oxybate) for the treatment of fibromyalgia syndrome. Enrollment in the first Phase III trial is expected to be completed during the next several months. Jazz Pharmaceuticals plans to announce top-line results from this Phase III clinical trial by year end. The second P
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic
2. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
3. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
4. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
5. Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008
6. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
7. Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR
8. Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR
9. Acura Pharmaceuticals, Inc. Announces Appointment of George K. Ross as Director
10. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
11. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 The Workgroup for ... authority on the use of health IT to ... full agenda for its annual fall conference, WEDI-Con ... WEDI-Con 2014 will take place at the HYATT ... attracting a diverse cross-section of payers, providers, government ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... The National Association of Hispanic Nurses ... Education Partnership Award (SEPA) grant from the National ... with the Hispanic Communications Network (HCN) entitled Hispanic ... NIH R25 program has been established to address ... health professionals by recruiting and interviewing bilingual role ...
(Date:8/20/2014)... Today, Zane Benefits, the #1 Online Health ... 2015. , According to Zane Benefits, with open enrollment ... are encouraged to start thinking about their healthcare needs. ... enrollment period will run from November 15, 2014 to ... purchase a new individual health insurance policy, or switch ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 Attendees ... get a sneak peak at Los Angeles’ first multi-faceted ... a tour of a blossoming 1.5-acre high school campus ... a shipping container farm in the L.A. Art District. ... diversity of sustainable urban agriculture, will kick off Seedstock’s ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 2Health News:Seedstock Sustainable Agriculture Conference’s Urban Farm Field Trip to Offer First Look at Los Angeles’ Premier Food Business Incubator 3
... and treated in many cases, say US doctors. In peripheral ... become blocked with the same kind of fatty deposits - ... of treating it is very simple - keep walking. While ... the ability to walk with ease. Positive effects are seen ...
... Nearly half of people with Parkinson's disease are using one ... as vitamins, message or acupuncture. Researchers at Johns Hopkins University ... than 200 people with Parkinson's disease. Forty per cent use ... cent use five or more different ones. There's no link ...
... Bubonic plague, the bacterium blamed for the Black Death ... biological weapon, has had its entire genome sequenced. The ... and picking up new genes from other microbes. ,That ... emerge. More ominously, it suggests that enhanced strains might ...
... with a skin condition called contact dermatitis may benefit from ... tomatoes, according to the results of a small study.// Individuals ... they come in contact with substances they are allergic to. ... the skin, and many people may not realize foods can ...
... New research confirms that the main ingredient in the -- ... loss when used long term. The younger you are when ... bone-related problems later in life. // ... our bone mass is constantly breaking down and re-building, usually ...
... Suppression of testosterone levels in men with testicular ... disease, warn US researchers.,A research team from North ... levels go down, a high rise in levels ... disease – occurs. They suggest that this phenomenon ...
Cached Medicine News:Health News:Sequencing of the Plague 2
(Date:8/20/2014)... WORTH, Fla. , Aug. 20, 2014  Glades Drugs, ... , is proud to announce its expansion into a ... , which will feature an 8,000-square-foot office space and state ... currently accepting applications for 100 open positions for the new ... at 4560 Lantana Road will serve as the chain,s corporate ...
(Date:8/20/2014)... , Aug. 20, 2014   Easy Breathe , the ... that its " Easy Blog " - has received more than ...   "We are thrilled that so many people are ... , CEO of Easy Breathe. "We,re committed to making sleep apnea ... Blog to stay informed about sleep apnea news , ...
(Date:8/20/2014)... YORK, Aug 20, 2014 Reportlinker.com announces ... in its catalogue: Global Patient Scales ... This report analyzes the worldwide markets for ... Product Segments: Floor Scales, Infant & Baby Scales, ... provides separate comprehensive analytics for the US, Canada, ...
Breaking Medicine Technology:Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 2Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 3Easy Breathe Blog Emerges as the Go-To Resource for Sleep Apnea Sufferers 4Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19
... , , , OSAKA, Japan, ... announced today positive results from PEARL 2 - a ... In this trial, both lurasidone 40 and 120 mg/day were significantly more ... an overall discontinuation rate that was similar to placebo. , , ...
... , , , ... CXM ) today announced that all patients enrolled in the Company,s ... and that it plans to provide detailed safety and efficacy data ... http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ) , , The Phase 2b MATRIX ...
Cached Medicine Technology:Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 2Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 3Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 4Lurasidone Demonstrated Efficacy in Treating Patients With Schizophrenia in Pivotal Phase 3 Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 8
... of the vocal cords in even the most ... like a standard laryngoscope, Viewmax® does not require ... its ability to allow intubation whether you are ... airway. It has a patented lens system that ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
... Greenspec Laryngoscopes are a high quality fiberoptic ... bringing greater standardization to fiberoptic laryngoscopes. The ... and indicates it's ability to interconnect with ... light offers a cool, bright and focused ...
... steel. Lamp supplied with blade. Oxygen ... operate on any standard/conventional handle allowing ... illumination without the potential confusion from ... blades offer an easy and cost ...
Medicine Products: